Evaluating the Role of Folate Receptor Alpha Expression in Ovarian Cancer

Published: Wednesday, Apr 17, 2019
The treatment landscape for ovarian cancer has rapidly progressed in recent years, particularly with the discovery of antiangiogenic agents and the emergence of PARP inhibitors. Despite these advances, high recurrence rates and low cure rates remain a significant challenge and new treatments are needed. One potential target that has emerged in recent years is folate receptor α (FRα), which is overexpressed in more than half of high-grade serous ovarian cancers. Multiple agents that target FRα have been developed and are currently under investigation for the treatment of ovarian cancer. This article explores the evolving ovarian cancer therapeutic spectrum, with an emphasis on FRα and its potential role among the current treatment options.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x